QuantaNovas commitment to purity and quality provides peace of mind to those who rely on consistent results
For example, in December 2024, Novo Nordisk bought three Catalent sites for US$11bn in order to boost its injectable drug capacity, and in December 2025, Eli Lilly announced new plans to build a US$6bn manufacturing facility in the US
Malek et al., 2016), coronary artery disease (Lee et al., 2015), and maintenance hemodialysis (Savica et al., 2005)
Two further points are worth knowing: Hair loss appears on the Foundayo label, reported in roughly 45% of users versus 2% on placebo, and more often in women (about 7%) than men (under 1%)
The purpose of this blend is to make all seven amino acids readily available so the body can make Glutathione as needed
Its practical usefulness can vary and depends on the individual context